nach oben

Erschienen in:

01.03.2020 | Guideline

Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision

verfasst von: Hirokazu Kashiwagi, Masataka Kuwana, Takaaki Hato, Toshiro Takafuta, Kingo Fujimura, Yoshiyuki Kurata, Mitsuru Murata, Yoshiaki Tomiyama, Committee for the Revision of “Reference Guide for Management of adult ITP” Blood Coagulation Abnormalities Research Team, Research on Rare and Intractable Disease supported by Health, Labour and Welfare Science Research Grants

Erschienen in: International Journal of Hematology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Excerpt

In 2012, ITP group of Blood Coagulation Abnormalities Research Team with funding from the Ministry of Health, Labour and Welfare Research Grant for Overcoming Intractable Diseases in Japan published a reference guide for management of adult immune thrombocytopenia (ITP) [1]. The reference guide was based on the existing global standards on ITP treatment, as well as research outcomes and expert opinions, and reflected the experience in Japan at that time. A feature of the reference guide was clarification of H. pylori-associated ITP, which is a unique characteristic of ITP cases in Japan. The reference guide also clarified the criteria for starting treatment for ITP, as well as the treatment target and presented a flowchart of treatment, with corticosteroids as first-line treatment, splenectomy as second-line and other treatments as third-line, together with the respective recommendation levels. The basic concepts of management of adult ITP have not changed significantly since that time, and the 2012 reference guide remains adequately effective. However, in the reference guide, thrombopoietin receptor agonists (TPO-RAs) were positioned as third-line treatment, as these products had only recently been approved in Japan. Since then, we have accumulated experience in the use of these drugs, and their long-term efficacy and safety continue to become clear. Furthermore, in 2017, the indications for rituximab, which has been positioned as second-line treatment in Europe and the US, were extended to adult ITP in Japan. Conversely, the number of patients undergoing splenectomy is declining, and there is an increasingly large divergence between decisions made in clinical practice and the reference guide regarding the selection of second-line treatment for patients resistant to corticosteroids. There is also an accumulation of new evidence on ITP treatment, including administration methods for corticosteroids used as first-line treatment, namely high-dose dexamethasone (HD-DEX). …

Fujimura K, Miyakawa Y, Kurata Y, Kuwana M, Tomiyama Y, Murata M. Reference guide for management of adult idiopathic thrombocytopenic purpura (ITP) 2012 version. J Jpn Soc Hematol. 2012;53(4):433–42.

Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guidelines for immune thrombocytopenia. Blood. 2011;117(16):4190–207.PubMed

Miyakawa Y, Kashiwagi H, Takafuta T, et al. Consensus report for the management of pregnancy with primary immune thrombocytopenia. Rinsho Ketsueki. 2014;55(8):934–47.PubMed

Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995–1008.PubMed

Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93.PubMed

Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93(3):329–35.PubMed

George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994;331(18):1207–11.PubMed

Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146(6):585–96.PubMed

McKenzie CG, Guo L, Freedman J, Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol. 2013;163(1):10–23.PubMed

10.

Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98(1):24–33.PubMed

11.

Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet. 1997;349(9064):1531–6.PubMed

12.

Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457–64.PubMedPubMedCentral

13.

Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.PubMed

14.

Kurata Y, Hayashi S, Kiyoi T, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol. 2001;115(5):656–64.PubMed

15.

Koike Y, Yoneyama A, Shirai J, et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost. 1998;79(6):1106–10.PubMed

16.

Sakuragi M, Hayashi S, Maruyama M, et al. Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders. Int J Hematol. 2015;101(4):369–75.PubMed

17.

Kuwana M, Kurata Y, Fujimura K, et al. Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi-center prospective study. J Thromb Haemost. 2006;4(9):1936–43.PubMed

18.

Kelton JG, Murphy WG, Lucarelli A, et al. A prospective comparison of four techniques for measuring platelet-associated IgG. Br J Haematol. 1989;71(1):97–105.PubMed

19.

Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998;352(9131):878.PubMed

20.

Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(2):237–46.PubMed

21.

Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113(6):1231–40.PubMed

22.

Arnold DM, Bernotas A, Nazi I, et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009;94(6):850–6.PubMedPubMedCentral

23.

Kikuchi T, Kobayashi T, Yamashita T, Ohashi K, Sakamaki H, Akiyama H. Eight-year follow-up of patients with immune thrombocytopenic purpura related to H. pylori infection. Platelets. 2011;22(1):61–4.PubMed

24.

Asahi A, Kuwana M, Suzuki H, Hibi T, Kawakami Y, Ikeda Y. Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica. 2006;91(10):1436–7.PubMed

25.

Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol. 2014;20(3):714–23.PubMedPubMedCentral

26.

The Japanese Society for Helicobacter Research Guideline Preparation Committee. Guideline for the Management of Helicobacter pylori (H. pylori) Infection in Japan 2016 Revision. Sentan Igaku-sha; 2016.

27.

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–46.PubMedPubMedCentral

28.

Fujimura K, Kuwana M, Kurata Y, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005;81(2):162–8.PubMed

29.

Ito T, Shiromizu T, Ohnishi S, et al. Potential role of extracellular vesicle-mediated antigen presentation in Helicobacter pylori hypersensitivity during eradication therapy. J Allergy Clin Immunol. 2018;142(2):672–6.PubMed

30.

Kuwana M, Ikeda Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol. 2005;81(2):106–12.PubMed

31.

McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364–9.PubMed

32.

George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guidelines developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40.PubMed

33.

Force BCfSiHGHT. Guideline for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574–96.

34.

Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the cooperative Latin American group on hemostasis and thrombosis. Blood. 1984;64(6):1179–83.PubMed

35.

Kusumoto S, Tanaka Y. Reactivation of hepatitis B virus and hepatitis C virus following immunosuppressive therapy. J Jpn Soc Intern Med. 2014;103(7):1645–53.

36.

Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994;330(22):1560–4.PubMed

37.

Arruda VR, Annichino-Bizzacchi JM. High-dose dexamethasone therapy in chronic idiopathic thrombocytopenic purpura. Ann Hematol. 1996;73(4):175–7.PubMed

38.

Caulier MT, Rose C, Roussel MT, Huart C, Bauters F, Fenaux P. Pulsed high-dose dexamethasone in refractory chronic idiopathic thrombocytopenic purpura: a report on 10 cases. Br J Haematol. 1995;91(2):477–9.PubMed

39.

Warner M, Wasi P, Couban S, Hayward C, Warkentin T, Kelton JG. Failure of pulse high-dose dexamethasone in chronic idiopathic immune thrombocytopenia. Am J Hematol. 1997;54(4):267–70.PubMed

40.

Stasi R, Brunetti M, Pagano A, Stipa E, Masi M, Amadori S. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis. 2000;26(6):582–6.PubMed

41.

Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004;83(12):764–8.PubMed

42.

Naithani R, Mahapatra M, Kumar R, Mishra P, Saxena R. High dose dexamethasone therapy shows better responses in acute immune thrombocytopenia than in chronic immune thrombocytopenia. Platelets. 2010;21(4):270–3.PubMed

43.

Nakazaki K, Hosoi M, Hangaishi A, Ichikawa M, Nannya Y, Kurokawa M. Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study. Intern Med. 2012;51(8):859–63.PubMed

44.

Sakamoto K, Nakasone H, Tsurumi S, et al. Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group. J Thromb Thrombolysis. 2014;37(3):279–86.PubMed

45.

Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349(9):831–6.PubMed

46.

Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401–7.PubMed

47.

Din B, Wang X, Shi Y, Li Y. Long-term effect of high-dose dexamethasone with or without low-dose dexamethasone maintenance in untreated immune thrombocytopenia. Acta Haematol. 2015;133(1):124–8.PubMed

48.

Praituan W, Rojnuckarin P. Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial. J Thromb Haemost. 2009;7(6):1036–8.PubMed

49.

Matschke J, Muller-Beissenhirtz H, Novotny J, et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 Study. Acta Haematol. 2016;136(2):101–7.PubMed

50.

Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296–302.PubMed

51.

Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016;3(10):e489–96.PubMed

52.

Rodeghiero F, Stasi R, Giagounidis A, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol. 2013;91(5):423–36.PubMed

53.

Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–36.PubMed

54.

Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16):1672–81.PubMed

55.

Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403.PubMed

56.

Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–99.PubMed

57.

Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol. 2011;94(1):71–80.PubMed

58.

Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118(1):28–36.PubMed

59.

Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–47.PubMed

60.

Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641–8.PubMed

61.

Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393–402.PubMed

62.

Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012;10(5):799–806.PubMed

63.

Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–23.PubMed

64.

Wang L, Gao Z, Chen XP, et al. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: a systematic review and meta-analysis. Sci Rep. 2016;6:39003.PubMedPubMedCentral

65.

Elgebaly AS, Ashal GE, Elfil M, Menshawy A. Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials. Clin Appl Thromb Hemost. 2017;23(8):928–37.PubMed

66.

Cines DB, Wasser J, Rodeghiero F, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017;102(8):1342–51.PubMedPubMedCentral

67.

Steurer M, Quittet P, Papadaki HA, et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice. Eur J Haematol. 2017;98(2):112–20.PubMed

68.

Gonzalez-Lopez TJ, Alvarez-Roman MT, Pascual C, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016;97(3):297–302.PubMed

69.

Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013;53(11):2807–12.PubMedPubMedCentral

70.

Mahevas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165(6):865–9.PubMed

71.

Cervinek L, Mayer J, Doubek M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol. 2015;102(1):7–11.PubMed

72.

Gonzalez-Lopez TJ, Pascual C, Alvarez-Roman MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40–3.PubMed

73.

Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639–45.PubMedPubMedCentral

74.

Nishimoto T, Numajiri M, Nakazaki H, Okazaki Y, Kuwana M. Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia. Int J Hematol. 2014;100(4):341–4.PubMed

75.

Oda A, Miyakawa Y, Druker BJ, et al. Thrombopoietin-induced signal transduction and potentiation of platelet activation. Thromb Haemost. 1999;82(2):377–84.PubMed

76.

Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010;95(7):1167–75.PubMedPubMedCentral

77.

Nørgaard M, Severinsen MT, Lund Maegbaek M, Jensen A, Cha S, Sørensen HT. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2012;159(1):109–11.PubMed

78.

Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2011;152(3):360–2.PubMed

79.

Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45.PubMed

80.

Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study. Am J Hematol. 2015;90(7):598–601.PubMed

81.

Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937–44.PubMedPubMedCentral

82.

Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28(3):437–44.PubMed

83.

Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018;5(3):e117–26.PubMed

84.

Oshima Y, Yuji K, Tanimoto T, Hinomura Y, Tojo A. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia. Intern Med. 2013;52(19):2193–201.PubMed

85.

Cuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol. 2010;47(3):289–98.PubMedPubMedCentral

86.

Zhang J, Liang Y, Ai Y, et al. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. PLoS One. 2018;13(6):e0198504.PubMedPubMedCentral

87.

Khellaf M, Viallard JF, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881–7.PubMedPubMedCentral

88.

Gonzalez-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169(1):111–6.PubMed

89.

Lakhwani S, Perera M, Fernandez-Fuertes F, et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 2017;99(4):372–7.PubMed

90.

Cantoni S, Carpenedo M, Mazzucconi MG, et al. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers. Am J Hematol. 2018;93(1):58–64.PubMed

91.

Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75–81.PubMed

92.

Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121(11):1976–81.PubMed

93.

Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14):2755–62.PubMed

94.

Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119(6):1356–62.PubMed

95.

Li Z, Mou W, Lu G, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93(1):91–8.PubMed

96.

Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9978):1653–61.PubMed

97.

Miyakawa Y, Katsutani S, Yano T, et al. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy. Int J Hematol. 2015;102(6):654–61.PubMed

98.

Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J, Mexican Hematology Study G. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol. 2007;86(12):871–7.PubMedPubMedCentral

99.

Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999–1004.PubMed

100.

Zwaginga JJ, van der Holt B, Te Boekhorst PA, et al. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica. 2015;100(3):e90–2.PubMedPubMedCentral

101.

Patel VL, Mahevas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–95.PubMedPubMedCentral

102.

Marangon M, Vianelli N, Palandri F, et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017;98(4):371–7.PubMed

103.

Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158(3):386–98.PubMed

104.

Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: Three different regimens. Am J Hematol. 2009;84(10):661–5.PubMedPubMedCentral

105.

Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–36.PubMed

106.

Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol. 2016;91(9):907–11.PubMed

107.

Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232–9.PubMed

108.

Arnold DM, Vrbensky JR, Karim N, et al. The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia. Br J Haematol. 2017;178(2):302–7.PubMed

109.

Porcelijn L, Huiskes E, Schipperus M, et al. Lack of detectable platelet autoantibodies is correlated with nonresponsiveness to rituximab treatment in ITP patients. Blood. 2017;129(25):3389–91.PubMed

110.

Feng R, Liu X, Zhao Y, et al. GPIIb/IIIa autoantibody predicts better rituximab response in ITP. Br J Haematol. 2018;182(2):305–7.PubMed

111.

Dierickx D, Verhoef G, Van Hoof A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009;266(5):484–91.PubMed

112.

Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834–40.PubMedPubMedCentral

113.

Venna N, Gonzalez RG, Camelo-Piragua SI. Case records of the Massachusetts General Hospital. Case 11-2010. A 69-year-old woman with lethargy, confusion, and abnormalities on brain imaging. N Engl J Med. 2010;362(15):1431–7.PubMed

114.

Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007;92(12):1695–8.PubMed

115.

Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329–34.PubMed

116.

Zaja F, Volpetti S, Chiozzotto M, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012;87(9):886–9.PubMed

117.

Tran H, Brighton T, Grigg A, et al. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol. 2014;167(2):243–51.PubMed

118.

Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2009;7(2):322–9.PubMed

119.

Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost. 2012;38(5):454–62.PubMed

120.

Borges da Silva H, Fonseca R, Pereira RM, Cassado Ados A, Alvarez JM, D’Imperio Lima MR. Splenic macrophage subsets and their function during blood-borne infections. Front Immunol. 2015;6:480.PubMedPubMedCentral

121.

Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018;131(11):1172–82.PubMedPubMedCentral

122.

Gonzalez-Porras JR, Escalante F, Pardal E, et al. Safety and efficacy of splenectomy in over 65-years-old patients with immune thrombocytopenia. Eur J Haematol. 2013;91(3):236–41.PubMed

123.

Zaja F, Barcellini W, Cantoni S, et al. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Am J Hematol. 2016;91(5):E293–5.PubMed

124.

Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–34.PubMed

125.

Kuramoto A, Oda K, Kawano H, et al. Multi-center study on long-term follow-up results of splenectomy Research team on Ministry of Health and Welfare designated ideopathic hematopoietic disorders (Team leader: Takao Murano). 1992 Res Rep. 1993;3:130–3.

126.

Weledji EP. Benefits and risks of splenectomy. Int J Surg. 2014;12(2):113–9.PubMed

127.

Sinwar PD. Overwhelming post splenectomy infection syndrome—review study. Int J Surg. 2014;12(12):1314–6.PubMed

128.

Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782–90.PubMedPubMedCentral

129.

Dolan JP, Sheppard BC, DeLoughery TG. Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century. Am J Hematol. 2008;83(2):93–6.PubMed

130.

Winslow ER, Brunt LM. Perioperative outcomes of laparoscopic versus open splenectomy: a meta-analysis with an emphasis on complications. Surgery. 2003;134(4):647–53.PubMed

131.

Rubin LG, Schaffner W. Clinical practice. Care of the asplenic patient. N Engl J Med. 2014;371(4):349–56.PubMed

132.

Mahevas M, Gerfaud-Valentin M, Moulis G, et al. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016;128(12):1625–30.PubMed

133.

Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007;110(10):3526–31.PubMed

134.

Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia. Blood. 2016;128(12):1547–54.PubMed

135.

Chang H, Tang TC, Hung YS, et al. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment. Eur J Haematol. 2018;101(4):549–55.PubMed

136.

Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115(1):29–31.PubMed

137.

Choi PY, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126(4):500–3.PubMedPubMedCentral

138.

Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85(2):351–8.PubMed

139.

Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost. 2013;11(11):1946–53.PubMed

140.

Lee JY, Lee JO, Jung JY, Bang SM. Dapsone therapy for refractory immune thrombocytopenia patients: a case series. Blood Res. 2017;52(2):95–9.PubMedPubMedCentral

141.

Oo T, Hill QA. Disappointing response to dapsone as second line therapy for primary ITP: a case series. Ann Hematol. 2015;94(6):1053–4.PubMed

142.

Ahn Y, Harrington W, Simon S, Mylvaganam R, Pall L, So A. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983;308(23):1396–9.PubMed

143.

Liu W, Gu X, Fu R, et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. Clin Appl Thromb Hemost. 2016;22(8):727–33.PubMed

144.

Weber E, Reynaud Q, Fort R, et al. Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: a PRISMA-compliant systematic review and meta-analysis of 28 studies. Medicine (Baltimore). 2017;96(37):e7534.PubMedPubMedCentral

145.

Stirnemann J, Kaddouri N, Khellaf M, et al. Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. Eur J Haematol. 2016;96(3):269–75.PubMed

146.

Audia S, Godeau B, Bonnotte B. Is there still a place for “old therapies” in the management of immune thrombocytopenia? Rev Med Intern. 2016;37(1):43–9.

147.

Taylor A, Neave L, Solanki S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015;171(4):625–30.PubMed

148.

Colovic M, Suvajdzic N, Colovic N, Tomin D, Vidovic A, Palibrk V. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets. 2011;22(2):153–6.PubMed

149.

Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81(1):19–25.PubMed

150.

Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang. 1987;52(3):206–11.PubMed

151.

Kurlander R, Coleman RE, Moore J, Gockerman J, Rosse W, Siegal R. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. Am J Med. 1987;83(4A):17–24.PubMed

152.

Alpdogan O, Budak-Alpdogan T, Ratip S, et al. Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. Br J Haematol. 1998;103(4):1061–3.PubMed

153.

Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359(9300):23–9.PubMed

154.

von dem Borne AE, Vos JJ, Pegels JG, Thomas LL, van der L. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed). 1988;296(6617):249–50.

155.

Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med. 1986;80(6):1051–4.PubMed

156.

Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost. 2008;100(5):762–5.PubMed

157.

Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008;83(2):122–5.PubMed

158.

Danese MD, Lindquist K, Gleeson M, Deuson R, Mikhael J. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol. 2009;84(10):631–5.PubMed

159.

Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AA. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015;125(9):1470–6.PubMedPubMedCentral

160.

British Committee for Standards in Haematology General Haematology Task Force. Guideline for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574–96.

161.

Zeidler K, Arn K, Senn O, Schanz U, Stussi G. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion. 2011;51(11):2269–76.PubMed

162.

Bishop JF, Schiffer CA, Aisner J, Matthews JP, Wiernik PH. Surgery in acute leukemia: a review of 167 operations in thrombocytopenic patients. Am J Hematol. 1987;26(2):147–55.PubMed

163.

Goodier CG, Lu JT, Hebbar L, Segal BS, Goetzl L. Neuraxial anesthesia in parturients with thrombocytopenia: a multisite retrospective cohort study. Anesth Analg. 2015;121(4):988–91.PubMed

Titel: Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision
verfasst von: Hirokazu Kashiwagi
Masataka Kuwana
Takaaki Hato
Toshiro Takafuta
Kingo Fujimura
Yoshiyuki Kurata
Mitsuru Murata
Yoshiaki Tomiyama
Committee for the Revision of “Reference Guide for Management of adult ITP” Blood Coagulation Abnormalities Research Team, Research on Rare and Intractable Disease supported by Health, Labour and Welfare Science Research Grants
Publikationsdatum: 01.03.2020
Verlag: Springer Singapore
Erschienen in: International Journal of Hematology / Ausgabe 3/2020
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-019-02790-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Alpha-hemoglobin-stabilizing protein (AHSP): a modulatory factor in β-thalassemia

Unusual megakaryocyte aggregation mimicking bone marrow carcinomatosis

A decision analysis comparing unrelated bone marrow transplantation and cord blood transplantation in patients with aggressive adult T-cell leukemia-lymphoma

Circulating intranuclear proteins may play a role in development of disseminated intravascular coagulation in individuals with acute leukemia

Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group

Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie